While contralateral breast cancer risk in BRCA1 and BRCA2 carriers has been well-described, there is a paucity of research on contralateral risk in LFS, owing to the low prevalence of germline TP53 PVs in the general population. This evidence concerns the gene BRCA1 and breast carcinoma.